Furthermore, clinical evidence of the overall survival showed that TUSC3 expression is positively correlated with patient outcome; specifically, high expression of TUSC3 significantly improves GBM patient survival, which was further confirmed by our Illumina methylation 850 EPIC arrays using 16 GBM-patient-derived samples. The gene discussed is TUSC3; the disease is glioblastoma.